Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1997-1-15
|
| pubmed:abstractText |
The aim of this study was to investigate the role of interleukin 6 (IL-6) in normal dendritic cell (DC) hematopoiesis. We used an enzyme-linked immunosorbent assay to quantitate IL-6 levels in CD34+ progenitor cell cultures favoring monocyte (mono) development versus those supporting mono-DC growth, and studied the neutralizing effects of alphaIL-6 antibody on DC hematopoiesis. IL6 levels in mono cultures (GM-CSF alone) were detected by day 4 and remained constant (approximately 100+ pg/ml) for 18 days. In mono-DC cultures, higher IL-6 levels correlated with DC content and development. Short-term mono-DC cultures initiated with GM-CSF + tumor necrosis factor (TNF) + stem cell factor (SCF) exhibited increases in IL-6 level until day 11 (peak DC growth). By day 18, the levels had declined and cells expressing typical DC features were no longer present. Long-term mono-DC cultures sustained with GM-CSF + TNF + SCF contained the highest IL-6 levels (671 pg/ml) on day 11. In these cultures, DCs and higher IL-6 levels persisted beyond 18 days. Anti-IL-6 profoundly inhibited cell proliferation associated with DC hematopoiesis when added on days 0, 2 and 5 to GM-CSF + TNF + SCF cultures, indicating that various stages of mono-DC development rely on IL-6. There was no reduction in the T cell response when alphaIL-6 was added to mixed leukocyte reaction cultures containing mature DCs as stimulators. Thus, alphaIL-6 appears to downregulate developmental processes associated with optimal mono-DC growth, but not the effector functions of mature DCs. These studies substantiate the importance of IL-6 as a secondary cytokine during DC development and provide insight into another control point in the DC pathway.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1066-5099
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
225-31
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8991542-Antibodies,
pubmed-meshheading:8991542-Cells, Cultured,
pubmed-meshheading:8991542-Dendritic Cells,
pubmed-meshheading:8991542-Fetal Blood,
pubmed-meshheading:8991542-Hematopoiesis,
pubmed-meshheading:8991542-Humans,
pubmed-meshheading:8991542-Interleukin-6,
pubmed-meshheading:8991542-Microscopy, Phase-Contrast
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Endogenously produced interleukin 6 is an accessory cytokine for dendritic cell hematopoiesis.
|
| pubmed:affiliation |
Division of Rheumatology, Allergy & Immunology, Winthrop University Hospital, Mineola, New York 11501, USA.
|
| pubmed:publicationType |
Journal Article
|